LynchBiologics.com | Pre-Clinical Studies
15584
page-template-default,page,page-id-15584,ajax_fade,page_not_loaded,,qode-theme-ver-6.2.1,wpb-js-composer js-comp-ver-4.3.5,vc_responsive
 

Pre-Clinical Studies

PRE-CLINICAL STUDY OBJECTIVES

LBIO’s new rhPDGF formulation ABSOLVE™ Bioactive Wound Dressing

  • 01 OBJECTIVE

    Weekly dosing, thereby improving patient compliance.

  • 02 OBJECTIVE

    Shorter dosing duration, thereby improving patient compliance and potentially improving safety.

  • 03 OBJECTIVE

    A sterile product that retains full potency, thereby improving patient safety

STUDY OVERVIEW

1.  Diabetic (db/db) mouse dermal wound model

2.  1.5cm x 1.5cm full thickness wounds

3.  15 animals, 5 animals per treatment group

4. Standardized photographs and clinical wound measurements obtained and recorded Days 0, 7, 14 and 21

5. Animals euthanized and biopsies collected on Day 21

DAY 21:  REPRESENTATIVE CLINICAL & HISTOLOGIC IMAGES

Control Collagen Wound Dressing (weekly)
ABSOLVE Wound Dressing (weekly)
Regranex (daily)

STUDY CONCLUSION

  • ABSOLVE™ promotes healing of diabetic wounds compared to collagen wound dressing plus buffer.
  • ABSOLVE™  treated wounds demonstrated improved angiogenesis, granulation tissue formation and re-epithelialization.
  • ABSOLVE™  wound dressing is much easier to use than competitors’ treatment.
  • ABSOLVE™ is a completely sterile formulation. Increasing patient safety.
  • ABSOLVE™ works with only Three weekly applications and appears as effective as 21 daily applications of competitors